G1 Therapeutics to Participate in Two Upcoming Conferences
On November 10, 2021, G1 Therapeutics (GTHX) announced participation in two virtual investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
On November 10, 2021, G1 Therapeutics (GTHX) announced participation in two virtual investor conferences. CEO Jack Bailey will present on November 17 at 8:00 AM EST at the Stifel 2021 Virtual Healthcare Conference. Additionally, he will engage in a fireside chat on December 1 at 12:35 PM EST during the 4th Annual Evercore ISI HealthCONx Conference. Both events will be webstreamed, accessible through the company's website. G1 Therapeutics focuses on developing cancer therapies, including its commercial product COSELA™.
Details
News Market Reaction – GTHX
The recorded move for GTHX in the trading session of this news was -2.25%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two upcoming virtual investor conferences.
- On November 17, 2021 at 8:00 AM EST, G1’s Chief Executive Officer Jack Bailey will present at the Stifel 2021 Virtual Healthcare Conference.
- On December 1, 2021 at 12:35 PM EST, Mr. Bailey will participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx Conference.
The webcast of both events will be accessible on the Events & Presentations page of http://www.g1therapeutics.com.
About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA™ (trilaciclib). G1 has a deep clinical pipeline and is executing a tumor-agnostic development plan evaluating trilaciclib in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.
Contacts:
Will Roberts
Vice President, Investor Relations & Corporate Communications
919-907-1944
wroberts@g1therapeutics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.